Cours Lexicon Pharmaceuticals, Inc. Nasdaq
Actions
US5288721047
Recherche biotechnologique et médicale
CA 2024 * | 25,81 M 23,57 M | CA 2025 * | 77,52 M 70,8 M | Capitalisation | 389 M 355 M |
---|---|---|---|---|---|
Résultat net 2024 * | -199 M -182 M | Résultat net 2025 * | -193 M -176 M | VE / CA 2024 * | 15,1 x |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | 5,02 x |
PER 2024 * |
-2,22
x | PER 2025 * |
-2,49
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 97,99% |
Dernier transcript sur Lexicon Pharmaceuticals, Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 07/07/14 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 01/01/99 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 02/08/21 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01/02/01 |
Ray Debbane
CHM | Chairman | 69 | 01/08/07 |
Director/Board Member | 65 | 28/08/07 |
Varia. 1 janv. | Capi. | |
---|---|---|
-2,31% | 103 Md | |
+0,56% | 95,28 Md | |
+1,69% | 22,15 Md | |
-17,37% | 21,02 Md | |
-9,30% | 18,15 Md | |
-41,01% | 16,73 Md | |
-14,85% | 16,05 Md | |
+3,21% | 13,68 Md | |
+33,54% | 12,17 Md |